As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib
Background. Combination therapy of transarterial chemoembolization plus sorafenib (TACE-S) has been proven to be safe and effective for hepatocellular carcinoma (HCC); however, this combination therapy is associated with a high incidence of adverse events (AEs). Our study focused on the relationship...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2019/2576349 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849304861034676224 |
|---|---|
| author | Lei Liu Enxin Wang Lin Li Dongyu Chen Kun Peng Mengmeng Wang Guohong Han |
| author_facet | Lei Liu Enxin Wang Lin Li Dongyu Chen Kun Peng Mengmeng Wang Guohong Han |
| author_sort | Lei Liu |
| collection | DOAJ |
| description | Background. Combination therapy of transarterial chemoembolization plus sorafenib (TACE-S) has been proven to be safe and effective for hepatocellular carcinoma (HCC); however, this combination therapy is associated with a high incidence of adverse events (AEs). Our study focused on the relationships between AEs and treatment outcomes and aimed to discover AE-based clinical markers that can predict the survival benefits of combination treatment. Methods. From January 2010 to June 2014, a total of 235 HCC patients treated with TACE-S were retrospectively enrolled. Major sorafenib-related AEs were prospectively recorded, and their correlations with overall survival (OS) were analysed using time-dependent covariate Cox regression analyses. Results. The majority of the patients (200, 85.1%) were male, and the median age was 51 years old. After two years of follow-up, the median OS of the study population reached 12.4 months. In all, 218 patients (92.8%) presented at least one AE, and 174 (74.0%) suffered AEs ≥2 grade. Based on time-dependent multivariate analyses, the development of hand-foot skin reaction (HFSR) ≥2 grade (HR = 0.43, 95% CI: 0.32–0.58, P<0.001) and diarrhoea ≥1 grade (HR = 0.72, 95% CI: 0.53–0.97, P=0.029) were identified as independent predictors of prolonged OS. Moreover, patients who developed both HFSR ≥2 grade and diarrhoea ≥1 grade achieved better outcomes than those patients who developed either or neither of these AEs (HR = 1.51, 95% CI: 1.11–2.06, P=0.009). Conclusions. The development of HFSR ≥2 grade or diarrhoea ≥1 grade during TACE-S treatment indicated prolonged OS, and these AEs should be considered important clinical markers for predicting patient prognoses. |
| format | Article |
| id | doaj-art-3fecab48eeab48efa9d95b96d315b1d6 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-3fecab48eeab48efa9d95b96d315b1d62025-08-20T03:55:36ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972019-01-01201910.1155/2019/25763492576349As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus SorafenibLei Liu0Enxin Wang1Lin Li2Dongyu Chen3Kun Peng4Mengmeng Wang5Guohong Han6Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology, Air Force Medical University, Xi’an 710032, ChinaDepartment of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi’an 710032, ChinaDepartment of Gastroenterology, The Second Affiliated Hospital of Air Force Medical University, Xi’an 710038, ChinaDepartment of Gastroenterology, The Second Affiliated Hospital of Air Force Medical University, Xi’an 710038, ChinaDepartment of Medical Imaging, 153th Central Hospital of the Chinese People’s Liberation Army, Zhengzhou 450100, ChinaDepartment of Drug and Equipment, Aeromedicine Identification and Training Centre of Air Force, 26 Huaqing Road, Lintong District, Xi’an 710069, ChinaDepartment of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi’an 710032, ChinaBackground. Combination therapy of transarterial chemoembolization plus sorafenib (TACE-S) has been proven to be safe and effective for hepatocellular carcinoma (HCC); however, this combination therapy is associated with a high incidence of adverse events (AEs). Our study focused on the relationships between AEs and treatment outcomes and aimed to discover AE-based clinical markers that can predict the survival benefits of combination treatment. Methods. From January 2010 to June 2014, a total of 235 HCC patients treated with TACE-S were retrospectively enrolled. Major sorafenib-related AEs were prospectively recorded, and their correlations with overall survival (OS) were analysed using time-dependent covariate Cox regression analyses. Results. The majority of the patients (200, 85.1%) were male, and the median age was 51 years old. After two years of follow-up, the median OS of the study population reached 12.4 months. In all, 218 patients (92.8%) presented at least one AE, and 174 (74.0%) suffered AEs ≥2 grade. Based on time-dependent multivariate analyses, the development of hand-foot skin reaction (HFSR) ≥2 grade (HR = 0.43, 95% CI: 0.32–0.58, P<0.001) and diarrhoea ≥1 grade (HR = 0.72, 95% CI: 0.53–0.97, P=0.029) were identified as independent predictors of prolonged OS. Moreover, patients who developed both HFSR ≥2 grade and diarrhoea ≥1 grade achieved better outcomes than those patients who developed either or neither of these AEs (HR = 1.51, 95% CI: 1.11–2.06, P=0.009). Conclusions. The development of HFSR ≥2 grade or diarrhoea ≥1 grade during TACE-S treatment indicated prolonged OS, and these AEs should be considered important clinical markers for predicting patient prognoses.http://dx.doi.org/10.1155/2019/2576349 |
| spellingShingle | Lei Liu Enxin Wang Lin Li Dongyu Chen Kun Peng Mengmeng Wang Guohong Han As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib Canadian Journal of Gastroenterology and Hepatology |
| title | As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib |
| title_full | As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib |
| title_fullStr | As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib |
| title_full_unstemmed | As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib |
| title_short | As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib |
| title_sort | as clinical markers hand foot skin reaction and diarrhea can predict better outcomes for hepatocellular carcinoma patients receiving transarterial chemoembolization plus sorafenib |
| url | http://dx.doi.org/10.1155/2019/2576349 |
| work_keys_str_mv | AT leiliu asclinicalmarkershandfootskinreactionanddiarrheacanpredictbetteroutcomesforhepatocellularcarcinomapatientsreceivingtransarterialchemoembolizationplussorafenib AT enxinwang asclinicalmarkershandfootskinreactionanddiarrheacanpredictbetteroutcomesforhepatocellularcarcinomapatientsreceivingtransarterialchemoembolizationplussorafenib AT linli asclinicalmarkershandfootskinreactionanddiarrheacanpredictbetteroutcomesforhepatocellularcarcinomapatientsreceivingtransarterialchemoembolizationplussorafenib AT dongyuchen asclinicalmarkershandfootskinreactionanddiarrheacanpredictbetteroutcomesforhepatocellularcarcinomapatientsreceivingtransarterialchemoembolizationplussorafenib AT kunpeng asclinicalmarkershandfootskinreactionanddiarrheacanpredictbetteroutcomesforhepatocellularcarcinomapatientsreceivingtransarterialchemoembolizationplussorafenib AT mengmengwang asclinicalmarkershandfootskinreactionanddiarrheacanpredictbetteroutcomesforhepatocellularcarcinomapatientsreceivingtransarterialchemoembolizationplussorafenib AT guohonghan asclinicalmarkershandfootskinreactionanddiarrheacanpredictbetteroutcomesforhepatocellularcarcinomapatientsreceivingtransarterialchemoembolizationplussorafenib |